What RNAgri does

RNAgri is a St. Louis, Missouri-based biotechnology company founded in 2011 that develops and produces ribonucleic acid (RNA) and RNA interference (RNAi) products. The company is positioned at the intersection of molecular biology and what appears to be agricultural biotechnology, based on its name and the involvement of agtech-focused investor The Yield Lab in its 2015 funding round. RNAgri operates with a small team of 1-10 employees and is led by John Killmer as Chief Executive Officer and Patrick McLaughlin as VP of Technology and Director of Molecular Biology — a configuration that signals a tightly run, technically driven organization centered on RNA science.

The company has raised approximately $2.9 million in cumulative disclosed funding across six rounds between 2012 and 2017, drawing on a regional St. Louis investor base including BioGenerator (a regional life sciences generator that provided initial seed support), St. Louis Arch Angels, the Allen Angel Capital Education Program (AACE), and The Yield Lab. No product details, customer relationships, pricing, or commercial channels are publicly disclosed, and no patents or certifications are listed in the source material.

The company's website (rnagri.com) currently resolves to a parked/redirect page, and no commercial milestones, leadership changes, or new funding events have been recorded since the July 2017 round. The combination of a multi-year absence of observable activity, undisclosed commercial metrics, and a non-functional public web presence limits the ability to characterize current operating status or revenue generation with confidence.

Name

RNAgri

Website

https://rnagri.com

Company type

Private

Founded year

2011

Headcount range

1–10 employees

Short description

RNAgri is a St. Louis-based biotech startup founded in 2011 that develops RNA and RNAi products, operating with 1-10 employees and having raised approximately $2.9M across six funding rounds through 2017, with no disclosed commercial activity since.

Ownership category

akta.pro rank

Product category

Agricultural Biotechnology

akta.pro primary industry

Transcriptomics & Gene Expression Profiling Services (HLAGANAE)

Keywords

• RNA products
• RNAi products
• Ribonucleic acid production
• Agricultural biotechnology
• Molecular biology reagents

Headquarters

HQ city

St Louis

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain

Core offering

RNAgri is a biotechnology startup that produces ribonucleic acid (RNA) and RNA interference (RNAi) products. The company focuses on the manufacturing of RNA-based biological products for agricultural and life-science applications, leveraging proprietary RNA production know-how and molecular biology expertise to deliver specialty RNA reagents.

Differentiator

Problem solved

Functional benefit

Products and services

• Ribonucleic acid (RNA) and RNA interference (RNAi) products Manufactured RNA and RNAi biological products supplied to organizations in agricultural biotechnology and life-science applications that require specialty ribonucleic acid inputs.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights1 record

Direct peers

• GreenLight Biosciences: GreenLight Biosciences develops RNA-based products for agriculture and human health, including RNAi-based crop protection. It is a direct peer to RNAgri given the overlap in RNA manufacturing for agricultural applications.
• TriLink BioTechnologies: TriLink BioTechnologies specializes in mRNA and oligonucleotide manufacturing, offering custom RNA synthesis services. It is a direct peer given its focus on commercial-scale RNA manufacturing similar to RNAgri's stated production capability.

Broad incumbents

• Alnylam Pharmaceuticals: Alnylam is the leading RNAi therapeutics company with approved products and a large pipeline. It is a broad incumbent peer given its dominant position in RNAi technology and manufacturing, overlapping with RNAgri's core competency.
• Ionis Pharmaceuticals: Ionis is a leading RNA-targeted therapeutics company with antisense oligonucleotide (ASO) technology. It is a broad incumbent peer given its RNA chemistry and manufacturing expertise in the broader RNA therapeutics space.
• Moderna: Moderna is a leader in mRNA therapeutics and vaccines with large-scale manufacturing infrastructure. It is a broad incumbent peer given its dominant position in RNA manufacturing at scale, though its focus is therapeutic rather than agricultural.
• Agilent Technologies: Agilent provides molecular biology tools, including oligonucleotide synthesis and genomics instruments. It is a broad incumbent peer given its overlap with RNAgri's RNA production and molecular biology expertise, though at a vastly larger scale.
• BioNTech: BioNTech is a major mRNA therapeutics and immunotherapy company with large-scale RNA manufacturing. It is a broad incumbent peer given its leadership in RNA-based product development and manufacturing technology.

Emerging players

• RNAissance Ag: RNAissance Ag is an early-stage company developing RNAi-based pest control solutions for agriculture. It is an emerging player peer directly competing with RNAgri in the agricultural RNAi niche with a similar science-led startup profile.

Regional players

• Syngenta: Syngenta is a global agribusiness with R&D into RNAi-based crop protection technologies. It is a regional peer in that it operates globally as a major agricultural inputs player, overlapping with RNAgri's likely agricultural RNAi focus as both a potential customer and competitor.

Others

• BioGenerator: BioGenerator is a St. Louis-based biotech startup generator and investor that has backed RNAgri. It is an "other" peer given its role as an investor/incubator rather than a direct competitor, but its portfolio overlaps with RNAgri's ecosystem and is thematically related.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RNAgri